55661-33-1

Basic information

• Product Name: 2-Thiazolemethanamine
• Synonyms: C-THIAZOL-2-YL-METHYLAMINE;2-Aminomethylthiazoledihydrochloride;Thiazol-2-yl-methylamine;2-AMINOMETHYLTHIAZOLE HYDROCHLORIDE 98%;2-AMINOMETHYLTHIAZOLE;2-Aminomethyl-1,3-thiazole;C-Thiazol-2-Yl-Methylamine dihydrochloride;2-Thiazolemethanamine
• CAS NO: 55661-33-1
• Molecular Formula: C₄H₆N₂S
• Molecular Weight: 114.17
• Product Categories: pharmacetical;Heterocycles;Amines;Aromatics;Intermediates
• Mol File: 55661-33-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: 180-185°C
• Boiling Point: 36 °C
• Flash Point: 104℃
• Appearance: /
• Density: 1.204 g/mL at 25 °C
• Vapor Pressure: 0.0085mmHg at 25°C
• Refractive Index: n20/D1.569
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7.24±0.40(Predicted)
• CAS DataBase Reference: 2-Thiazolemethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolemethanamine(55661-33-1)
• EPA Substance Registry System: 2-Thiazolemethanamine(55661-33-1)

Safety Data

• Hazard Codes: Xi,C
• Statements: 22-34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2735PSN1 8 / PGII
• HazardClass: IRRITANT, HYGROSCOPIC, CORROSIVE
• Hazardous Substances Data: 55661-33-1(Hazardous Substances Data)

Usage

Chemical Properties

Off-white to cream color solid

Uses

(2-Thiazolyl)methylamine is a useful compound in the preparation of cephalosporins

InChI:InChI=1/C4H6N2S.2ClH/c5-3-4-6-1-2-7-4;;/h1-2H,3,5H2;2*1H

Upstream product

• 107-20-0 2-chloroethanal 
• 55443-42-0 N-(2-amino-2-thioxoethyl)benzamide 
• 17356-08-0 thiourea 
• 78-95-5 chloroacetone 
• 103863-35-0 N-thiazol-2-ylmethyl-phthalimide 
• 13838-77-2 1,3-thiazole-2-carbaldehyde oxime 
• 171268-82-9 thiazol-2-yl-methylazide 
• 7732-18-5 water 
• 10200-59-6 Thiazole-2-carbaldehyde 

Downstream Products

• 1596-65-2 2-amino-3-(2-thiazolyl)propanoic acid 
• 1072804-38-6 2-(1-(4-fluorobenzyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)-4-methyl-N-(thiazol-2-ylmethyl)thiazole-5-carboxamide 
• 185747-16-4 (thiazol-2-yl)methylcarbamic acid t-butyl ester 
• 1417790-13-6 C₂₁H₁₉F₃N₆O₂S 
• 1123819-38-4 C₂₆H₁₇F₃N₄O₂S 
• 1123819-30-6 C₂₅H₁₇F₃N₄O₂S 
• 1123819-11-3 C₂₄H₁₇ClN₄O₂S 
• 1123818-90-5 C₂₄H₁₈N₄O₂S 
• 1219623-44-5 2-(2-oxo-3,3-diphenylpyrrolidin-1-yl)-N-(1,3-thiazol-2-ylmethyl)acetamide 
• 1202927-41-0 2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(thiazol-2-ylmethyl)isonicotinamide 
• 1191942-78-5 3,5-di-tert-butyl-4-hydroxy-N-(1-(thiazol-2-ylmethylcarbamoyl)cyclopropyl)benzamide 
• 530090-23-4 (Z)-2-{1-[2-chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(thiazol-2-ylmethyl)acetamide 
• 1018480-47-1 C₁₆H₁₃F₃N₄O₂S₂ 
• 165668-08-6 C₆H₈N₂SO 

Relevant articles and documents

Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model

Colony-stimulating factor-1 receptor (CSF1R) is implicated in tumor-associated macrophage (TAM) repolarization and has emerged as a promising target for cancer immunotherapy. Herein, we describe the discovery of orally active and selective CSF1R inhibitors by property-driven optimization of BPR1K871 (9), our clinical multitargeting kinase inhibitor. Molecular docking revealed an additional nonclassical hydrogen-bonding (NCHB) interaction between the unique 7-aminoquinazoline scaffold and the CSF1R hinge region, contributing to CSF1R potency enhancement. Structural studies of CSF1R and Aurora kinase B (AURB) demonstrated the differences in their back pockets, which inspired the use of a chain extension strategy to diminish the AURA/B activities. A lead compound BPR1R024 (12) exhibited potent CSF1R activity (IC50 = 0.53 nM) and specifically inhibited protumor M2-like macrophage survival with a minimal effect on antitumor M1-like macrophage growth. In vivo, oral administration of 12 mesylate delayed the MC38 murine colon tumor growth and reversed the immunosuppressive tumor microenvironment with the increased M1/M2 ratio.

COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELL GROWTH

The invention relates to compounds of the formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R4, R5, n, A and B are as defined herein. The inventi

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.